锐客网

  1. 首页 > 生活杂烩 > 健康 > >

高血压|辞旧迎新，SPC逐鹿高血压再下一城( 二 )


[5]Joint Committee for Guideline Revision. 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. J Geriatr Cardiol. 2019 Mar;16(3):182-241.
[6] Task Force of the Latin American Society of Hypertension. Guidelines on the management of arterial hypertension and related comorbidities in Latin America. J Hypertens. 2017 Aug;35(8):1529-1545.
[7] Tay JC, Sule AA, Chew EK, Tey JS, Lau T, Lee S, Lee SH, Leong CK, Lim ST, Low LP, Oh VM, Phoon KY, Tan KW, Wu A, Yeo LS. Ministry of Health Clinical Practice Guidelines: Hypertension. Singapore Med J. 2018 Jan;59(1):17-27. doi: 10.11622/smedj.2018007. PMID: 29376186.
[8]Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 Jun;71(6):e13-e115.
[9] Chen X, Xu SK, Guo QH, Hu Z, Wang HY, Yu J, Li WH, Tang GB, Zhang HF, Li Y, Wang JG. Barriers to blood pressure control in China in a large opportunistic screening. J Clin Hypertens (Greenwich). 2020 May;22(5):835-841.
[10] Campana E, Cunha V, Glaveckaite S, Gruev I, Lamirault G, Lehmann E, Masi S, Mfeukeu Kuate L, Mishshenko L, Ona DID, Oo MZ, Tautu OGF, Vachulova A, Vintila AM, Wolf J, Zvartau N, Narkiewicz K, Laurent S. The use of single-pill combinations as first-line treatment for hypertension: translating guidelines into clinical practice. J Hypertens. 2020 Dec;38(12):2369-2377.
[12] Karpov YA, Gorbunov VM, Deev AD. Effectiveness of Fixed-Dose Perindopril/Amlodipine on Clinic, Ambulatory and Self-Monitored Blood Pressure and Blood Pressure Variability: An Open-Label, Non Comparative Study in the General Practice. High Blood Press Cardiovasc Prev. 2015 Dec;22(4):417-25.
[13] Abdelhady A, Khader S, Sinnuqrut S, Albow A. The Efficacy of Perindopril/Amlodipine in Reaching Blood Pressure Targets: Results of the CONTROL Study. Clin Drug Investig. 2016 May;36(5):357-66.
[14] Glezer MG. [Antihypertensive Effect of Switching to a Fixed Perindopril/Amlodipine Combination in Patients Ineffectively Treated by Free Sartan-Containing Combinations. Results of the AVANGARD Study]. Kardiologiia. 2019 Oct 14;59(10):31-38. Russian.
[15] Dahl?f B, Sever P S, Poulter N R, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BP[J]. Lancet, 2005, 366(9489):895-906.
[16] Gupta A, Mackay J, Whitehouse A, et al. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet. 2018 Sep 29;392(10153):1127-1137.
专家简介
高血压|辞旧迎新，SPC逐鹿高血压再下一城
文章图片


陈瑞珍教授
复旦大学附属中山医院心内科主任医师 ， 教授 ， 医学博士 ， 博士生导师 。
上海市心血管病研究所中心实验室副主任 ， 教育部新世纪优秀人才计划入选者 ， 上海市优秀学术带头人 。国际心脏研究会会员、欧洲心脏病学会会员、欧洲心力衰竭协会会员、中华医学会心血管病学分会心力衰竭学组委员、ISHR中国转化医学工作委员会委员、中国医疗保健国家交流促进会精准心血管病分会常务委员、中国医师协会中西医结合分会心脏康复专家委员会委员、中国中药协会心血管药物临床研究专业委员会委员、中国心衰中心联盟委员 。主要从事内科心血管疾病的临床与基础研究 ， 尤其是对病毒性心肌炎与扩张型心肌病、心力衰竭、高血压等有长期深入的研究 。主持国家自然科学基金课题6项 ， 作为负责人或主要PI承担国家及省部级科研课题20余项 。在Circulation、Circulation Research、Europe Heart Failure、J Viol、IJC等杂志发表SCI收录论著70余篇 ， 中文核心期刊发表论著100余篇 。获国家科技进步二等奖、省部级科技进步奖十余项以及上海市巾帼创新奖、明治乳业生命科学奖、上海市三八红旗手标兵等 。

推荐阅读


上一篇：非酒精性脂肪性肝病|脂肪肝患者该怎么减重？这10条AGA专家建议请收好！

下一篇：病例对照研究|病例对照研究：常见口腔细菌多，竟然和食管癌有关……？